AI, Personalisation, and Connected Health Will Redefine Pharma and Life Sciences in 2026
· Posted on: January 28th 2026 · read
Pharma and life sciences are on the brink of major change. Technology is moving fast, and consumers are demanding more control over their health.
In 2026, three trends will dominate: AI becoming a core part of research, personalised health going mainstream, and connected devices transforming patient care.
Here’s what that means and why businesses need to start planning now.
AI will be a game changer for R&D
AI isn’t just a buzzword anymore, rather it’s becoming central to drug discovery and development. It can crunch huge datasets, predict how molecules behave, and speed up clinical trials. The benefits are lower costs and faster timelines for getting treatments to market.
But there’s a catch: AI isn’t perfect. If it gets something wrong, the consequences could be serious. That’s why regulation and validation will matter more than ever. Expect new compliance rules and ethical standards to emerge alongside innovation. For businesses, the challenge is clear - move fast, but don’t cut corners.
Personalised health will go mainstream
People want more control over their health, and they want solutions tailored to them. This trend, accelerated by the pandemic, is driving demand for personalised supplements, medicines, and health plans.
We’ve already seen at-home testing kits for food intolerances and vitamin deficiencies take off. Next up? Products based on genetic data, lifestyle habits, and personal goals like boosting energy or improving digestion. For pharma and wellness brands, this means building personalisation into product development and marketing strategies.
Connected devices will change the game
Wearable tech is just the beginning. In 2026, expect more devices that monitor health in real time, from smartwatches and glucose monitors to sensors that sit inside the body.
For patients, this means convenience: fewer trips to the clinic for routine checks. For doctors, it means better data for diagnosis and treatment.
But, for pharma? A huge opportunity to use real-world data to improve research and patient support. Partnerships between pharma and tech companies will become more common as data becomes the new currency in healthcare.
What businesses should do now
2026 will be a year of convergence, in that AI, personalisation, and connected health will reshape the industry. Companies that act now will lead the way.
- Businesses absolutely must invest in AI, but do it responsibly. They need to build compliance and validation into every step.
- Embracing personalisation is key, as consumers expect tailored solutions, so make it part of your offering.
- Leveraging data partnerships is important - work with device makers and tech platforms to access real-time insights.
Predictions 2026 e-book
MHA Predictions 2026
Download our e-book now
